

Glioblastoma / Anaplastic Astrocytoma

Pharm-Olam is currently partnering with a sponsor company in the development of a treatment for Glioblastoma / Anaplastic Astrocytoma. This type of brain tumor has very few available therapies, so this study's goal is to assist in potentially identifying additional effective treatment options.

Study Overview

A Phase II/III study for the treatment of Recurrent Glioblastoma / Anaplastic Astrocytoma

Therapeutic Area

Oncology

Patient Population

100+

Sites & Locations

60 across North America, Western Europe and Middle East

Services Provided

- Regulatory
- Monitoring
- Project Management
- Quality Assurance

Status

Enrollment Complete

Experience & Insights

Pharm-Olam's Oncology team is led by Dr. Dhiraj Abhyankar, a Medical Oncologist with over 15 years of experience at both pharmaceutical and clinical research organizations.

With more than 25% of Pharm-Olam's total study portfolio in Oncology-related studies, Pharm-Olam was the right partner for this specialized trial.

For more information about Pharm-Olam, please visit
www.pharm-olam.com

About Pharm-Olam International

A multinational Contract Research Organization (CRO), Pharm-Olam offers comprehensive clinical research services to the pharmaceutical, biotechnology and medical device industries. From Phase I to Phase IV, Pharm-Olam focuses on delivering high-quality data, achieving targeted enrollment and meeting projected timelines.

Pharm-Olam makes clinical research....**Easy As I, II, III, IV™**.

